We report the case of a patient with gastric adenocarcinoma with multiple liver metastases. This patient showed complete remission for more than 68 months after S-1/cisplatin combination chemotherapy and radical total gastrectomy. The patient, a 63-year-old man, presented with dyspepsia and difficulty in swallowing. Endoscopic findings showed a huge ulcero-infiltrative mass at the lesser curvature of the mid-body, extending to the distal esophagus. Biopsy revealed a poorly differentiated tubular adenocarcinoma. An abdominal computed tomography scan demonstrated multiple hepatic metastases. S-1/cisplatin combination chemotherapy was initiated, and following completion of six cycles of chemotherapy, the gastric masses and hepatic metastatic lesions had disappeared on abdominal computed tomography. Radical total gastrectomy and D2 lymphadenectomy combined with splenectomy were performed. The patient underwent three cycles of S-1/cisplatin combination chemotherapy followed by tegafur-uracil therapy for 1 year. He remained in complete remission for more than 68 months after surgery.
Introduction
Gastric cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide. 1 Surgery is the main treatment strategy for gastric cancer; only R0 resection anticipates a potential cure. It is very difficult to achieve complete remission (CR) in metastatic gastric cancer; palliative chemotherapy is the main treatment option. A median overall survival of 8 to 13 months has been reported in patients undergoing chemotherapy, while this drops to 3 to 5 months for those treated with best supportive care. [2] [3] [4] Rare reports have presented good therapeutic results for metastatic gastric cancer treated with chemotherapy and/or surgical treatment. [5] [6] [7] However, in most of these reports, CR did not last for more than 5
years.
Here, we report a case of gastric adenocarcinoma with multiple liver metastases that showed CR for more than 68 months after S-1/cisplatin combination chemotherapy followed by radical total gastrectomy.
Case Report
A 63-year-old man presented with anorexia, dyspepsia, and difficulty swallowing in January 2010. Endoscopic findings showed a huge ulcero-infiltrative mass at the lesser curvature of the mid-body, extending to the distal esophagus (Fig. 1A, B) . Biopsy revealed a poorly differentiated tubular adenocarcinoma (Fig. 2 ).
An abdominal computed tomography (CT) scan demonstrated irregular wall thickening on the lesser curvature side of the gastric upper body with perigastric fat invasion and multiple metastases to neighboring lymph nodes (Fig. 3A) . The CT scan also revealed multiple hepatic metastatic lesions (1.0 to 1.6 cm in size over the entire liver) (Fig. 3A~C) . A diagnosis of stage IV (cT3N3M1) advanced gastric cancer was made according to the 7th American Joint Committee on Cancer (AJCC) system.
We administered S-1/cisplatin combination chemotherapy. showed that the gastric mass had almost disappeared and that the hepatic metastatic nodules that had been previously observed were no longer present (Fig. 4A, B) . To confirm the absence of the hepatic metastatic lesions, we performed a magnetic resonance imaging scan of this liver; this did not detect any metastatic lesions in the liver. Follow-up endoscopy showed that the gastric cardia mass had disappeared and an erosive lesion at the site of the previous mass was all that remained (Fig. 1C, D) . The patient was transferred to the surgery department. Mitomi et al. 6 reported a CR duration of 50 months in a patient with advanced gastric cancer with paraaortic lymph node metastases after S-1 monotherapy followed by total gastrectomy.
Suzuki et al. 7 reported that a patient treated with S-1 monotherapy maintained CR for 4 years without gastrectomy. As observed in these cases, S-1 may induce a very surprising response in a subgroup of advanced gastric cancer patients. This requires further study.
Currently, the most frequently used adjuvant chemotherapy regimens for gastric cancer after curative surgery are S-1 monotherapy and capecitabine/oxaliplatin combination chemotherapy.
Patients with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph node dissection followed by adjuvant S-1 chemotherapy showed a 3-year overall survival rate of 80.1%. 10 Our patient refused to take the oral S-1 drug. images revealed that some of the hepatic metastatic lesions had disappeared; those in liver segments 3 and 6 lesions persisted, although they measured less than 1 cm in size. As a result, we could only consider liver metastasis for the pathology of the liver lesions at the time of the initial diagnosis, and these lesions were expected to respond to S-1/cisplatin chemotherapy.
In conclusion, we report the case of a patient with stage IV gastric cancer with liver metastases who was treated with S-1/ cisplatin combination chemotherapy and radical total gastrectomy, achieved CR, and maintained remission for more than 68 months after surgery.
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